Capstan Therapeutics

Today, we announced a definitive agreement under which AbbVie will acquire Capstan, including CPTX2309, a potential first-in-class clinical-stage in vivo CAR-T therapy, being developed for the treatment of autoimmune diseases. AbbVie’s position as a world-leader in immunology moves us closer to delivering on our mission to multiply the possibilities and transform patient care globally. We are grateful for the contributions of our team, our scientific founders, and our investors, that have positioned Capstan as the leader in in vivo CAR-T. Learn more in today’s announcement: https://lnkd.in/eSJ4geqq

For more than two decades, we’ve been working to deepen our understanding of autoimmune disease drivers and deliver treatments that help more patients reach their treatment goals.  Now with Capstan Therapeutics, we aim to transform the standard of care again with therapies that have the potential to reset the immune system to approach a functional cure.  

JUST IN: We’ve signed a definitive agreement to acquire Capstan Therapeutics. This agreement underscores our commitment to drive scientific innovation and transform patient care in #immunology. Learn more: https://bit.ly/4nta43y [Video description: On-screen text reads, "Immunology News."]

We are pleased to announce the promotions of three of our team members - Miguel Arcinas, Haig Aghajanian, and Atia Naim. Thank you all for your contributions and leadership, which have been key to advancing Capstan and our mission to multiply the possibilities for patients.

Many people living with #autoimmune diseases face a long and difficult treatment journey. Currently available therapies often mean chronic immunosuppression, which can lead to unwanted side effects like fatigue and being more prone to infections. There is no one-size-fits-all approach — patients may need to try multiple medications, adjust dosages, or combine therapies just to manage their symptoms… and many patients still don’t achieve remission. At Capstan, we’re working to change that. We’re developing a new approach called in vivo CAR-T that temporarily directs the body’s immune system to attack B cells that cause disease. The goal of this therapy is to “reset” the body's B cells in a manner that is designed to be: ✔️ Safe, targeted, and durable ✔️Administered without chemotherapy (lymphodepletion) or leukapheresis, which is required for first-generation CAR-T therapies ✔️ Delivered in an outpatient setting ✔️ Customizable and re-dosable, depending on patient needs This June, we recognize Scleroderma Awareness Month and Myasthenia Gravis Awareness Month and honor the resilience of those living with these conditions. At Capstan, we are reaffirming our commitment to advancing innovation that puts patients first. #SclerodermaAwarenessMonth #MGAwarenessMonth

We're proud to share our preclinical publication in Science Magazine, which represents the culmination of years of discovery, improvements, and grit at Capstan. This paper highlights our in vivo engineering strategy and preclinical development of our lead in vivo CAR-T program, CPTX2309, that is now in the clinic. Key takeaways:  • The study showed the ability to generate CD8+ CAR-T cells in vivo, driving deep B cell depletion in preclinical models with a compact two-dose cycle of CPTX2309 using a transient, mRNA-based approach.  • After depletion, reconstituted B cells were predominantly naive, indicative of an immune reset and potential for durable response.  • These results support the ongoing clinical development of CPTX2309 for treatment of autoimmune diseases. Read the full paper here: https://lnkd.in/gpYR-6y8

This week, we are in Boston attending Biotechnology Innovation Organization (BIO) 2025! Join Adrian Bot, M.D., Ph.D., our CSO and EVP of R&D, as he participates in a panel focused on how in vivo CAR-T is poised to revolutionize immunotherapy. #BIO25

Today, we announced the successful dosing of the first participants in Capstan’s Phase 1 trial of our lead in vivo CAR-T therapy for autoimmune diseases. This milestone marks an important inflection point in Capstan’s four-year journey to establish itself as the leader in the in vivo CAR-T field… and we’re only getting started!   A huge shoutout to our incredible Capstaneers for their tireless efforts in developing a transformational product that has the potential to greatly improve patient outcomes. Your dedication and hard work have made this achievement possible!    Read more about CPTX2309 in our press release: https://lnkd.in/efuBE75v

Today, we announced the successful dosing of the first participants in Capstan’s Phase 1 trial of our lead in vivo CAR-T therapy for autoimmune diseases. This milestone marks an important inflection point in Capstan’s four-year journey to establish itself as the leader in the in vivo CAR-T field… and we’re only getting started!   A huge shoutout to our incredible Capstaneers for their tireless efforts in developing a transformational product that has the potential to greatly improve patient outcomes. Your dedication and hard work have made this achievement possible!    Read more about CPTX2309 in our press release: https://lnkd.in/efuBE75v

It is estimated that over 15 million people in the U.S. are living with at least one #autoimmune disease, including myositis, lupus, vasculitis, and rheumatoid arthritis, all of which are being recognized in the month of May.   At Capstan, we are harnessing the power of in vivo CAR-T therapy to reset the immune system. Our vision is to deliver safe, tunable, and scalable therapies that may result in durable clinical outcomes for patients with autoimmune disorders. Learn more about the science behind Capstan: https://bit.ly/4mi0Ma0   #MyositisAwarenessMonth #LupusAwarenessMonth #VasculitisAwarenessMonth #ArthritisAwarenessMonth